Mark Trusheim
Senior Strategy Advisor, NEWDIGS Tufts Medical Center
Mark Trusheim is senior strategy advisor of NEWDIGS at Tufts Medical Center. Mark’s research focuses on the economics of biomedical innovation, especially payment innovations for biopharmaceuticals and gene therapies, biosimilars, and precision medicine. Mark held appointments for 18 years at MIT Sloan in applied economics and has served as a special government employee for the FDA’s Office of the Commissioner. Mark is also president of Co-Bio Consulting, LLC. His career has spanned policy as the president of the Massachusetts Biotechnology Council, diagnostics as founder of Cantata Labs, genomics as president of Cereon Genomics, eHealth as vice president of Monsanto Health Solutions, managed care marketing at Searle Pharmaceuticals, and big data at Kenan Systems. He holds degrees in chemistry from Stanford University and management from MIT.
